SHIFT

Systolic Heart failure treatment with the lf inhibitor ivabradine Trial

Skip to content
  • Home
  • SHIFT
  • IVABRADINE
  • HEART RATE & HEART FAILURE
  • NEWSROOM
  • RESOURCES
  • CONTACT US
Home > newsroom > News from congresses

News from congresses

  • Heart Failure Congress 2015:
    Ivabradine is effective in chronic heart failure patients whatever the number of comorbidities
  • The American College of Cardiology 2015:
    Ivabradine is effective in chronic heart failure patients with or without angina
  • Heart Failure Congress 2014:
    The efficacy and safety of ivabradine are similar in diabetic and nondiabetic patients
  • ESC Congress 2013:
    Ivabradine’s clinical benefits in CHF are maintained with or without renal dysfunction
    The benefits and tolerability of ivabradine are similar irrespective of blood pressure
    SHIFT is the basis of a prognostic model for heart failure patients
    Ivabradine’s efficacy and safety are maintained with or without COPD
This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information. This site is published and updated by the SHIFT study investigators-©2021 SHIFT. All rights reserved. Report a side-effect with a drug.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more